EPI-743 in Friedreich's Ataxia Point Mutations
Location: University of South Florida
Details: The University of South Florida (USF) in Tampa, FL is looking for adults ages 18-65 to complete a trial for EPI-743 in patients with point mutations. This is a Phase 2A Clinical Trial for Edison Pharmaceutical's EPI-743, also known as Vincerinone™, which aims to improve mitochondrial function by reducing oxidative stress. All participants will receive 400mg of EPI-743 three times daily for 3 months. The sponsor of the trial is Edison Pharmaceuticals, Inc. and the study's lead investigator is Theresa Zesiewicz, MD.
To be eligible for participation, genetic confirmation of Friedreich’s Ataxia is required. Additional eligibility details are available at: www.clinicaltrials.gov/ct2/show/NCT01962363
If you are interested in participating, please contact the study coordinator below: